Actinogen Medical Limited (FRA:3AC)

Actinogen Medical Statistics

Total Valuation

FRA:3AC has a market cap or net worth of EUR 98.42 million. The enterprise value is 90.96 million.

Market Cap	98.42M
Enterprise Value	90.96M

Important Dates

The last earnings date was Monday, November 24, 2025.

Earnings Date	Nov 24, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	3.18B
Shares Outstanding	n/a
Shares Change (YoY)	+37.04%
Shares Change (QoQ)	+4.26%
Owned by Insiders (%)	16.38%
Owned by Institutions (%)	4.65%
Float	2.46B

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	32.12
PB Ratio	9.62
P/TBV Ratio	10.65
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-11.06
EV / Sales	29.40
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-21.46

Financial Position

The company has a current ratio of 3.76, with a Debt / Equity ratio of 0.18.

Current Ratio	3.76
Quick Ratio	3.74
Debt / Equity	0.18
Debt / EBITDA	n/a
Debt / FCF	-0.43
Interest Coverage	-314.06

Financial Efficiency

Return on equity (ROE) is -77.47% and return on invested capital (ROIC) is -46.12%.

Return on Equity (ROE)	-77.47%
Return on Assets (ROA)	-41.91%
Return on Invested Capital (ROIC)	-46.12%
Return on Capital Employed (ROCE)	-82.89%
Revenue Per Employee	510,762
Profits Per Employee	-1.37M
Employee Count	6
Asset Turnover	0.24
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +133.33% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+133.33%
50-Day Moving Average	0.02
200-Day Moving Average	0.02
Relative Strength Index (RSI)	64.46
Average Volume (20 Days)	13,850

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, FRA:3AC had revenue of EUR 3.06 million and -8.22 million in losses. Loss per share was -0.00.

Revenue	3.06M
Gross Profit	3.06M
Operating Income	-8.57M
Pretax Income	-8.22M
Net Income	-8.22M
EBITDA	-8.38M
EBIT	-8.57M
Loss Per Share	-0.00

Balance Sheet

The company has 9.21 million in cash and 1.82 million in debt, giving a net cash position of 7.39 million.

Cash & Cash Equivalents	9.21M
Total Debt	1.82M
Net Cash	7.39M
Net Cash Per Share	n/a
Equity (Book Value)	10.24M
Book Value Per Share	0.00
Working Capital	9.20M

Cash Flow

In the last 12 months, operating cash flow was -4.22 million and capital expenditures -21,225, giving a free cash flow of -4.24 million.

Operating Cash Flow	-4.22M
Capital Expenditures	-21,225
Free Cash Flow	-4.24M
FCF Per Share	n/a

Margins

Gross margin is 100.00%, with operating and profit margins of -279.70% and -268.37%.

Gross Margin	100.00%
Operating Margin	-279.70%
Pretax Margin	-268.37%
Profit Margin	-268.37%
EBITDA Margin	-273.48%
EBIT Margin	-279.70%
FCF Margin	n/a

Dividends & Yields

FRA:3AC does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-37.04%
Shareholder Yield	-37.04%
Earnings Yield	-8.36%
FCF Yield	-4.31%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on December 3, 2013. It was a reverse split with a ratio of 0.5.

Last Split Date	Dec 3, 2013
Split Type	Reverse
Split Ratio	0.5

Scores

FRA:3AC has an Altman Z-Score of 3.03 and a Piotroski F-Score of 1.

Altman Z-Score	3.03
Piotroski F-Score	1